Biotechnology
Healthcare
Investing News
Market News
Technology
The Market Buzz
Protalix BioTherapeutics and Chiese Global Rare Diseases Report Topline Results from the Phase III BALANCE Clinical Trial
Protalix BioTherapeutics Inc. (NYSE: PLX) has reported topline results from the BALANCE pivotal Phase III clinical trial evaluating pegunigalsidase alfa (PRX–102), 1 mg/kg, administered every two weeks. “We are pleased...